JP2017526698A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017526698A5 JP2017526698A5 JP2017512759A JP2017512759A JP2017526698A5 JP 2017526698 A5 JP2017526698 A5 JP 2017526698A5 JP 2017512759 A JP2017512759 A JP 2017512759A JP 2017512759 A JP2017512759 A JP 2017512759A JP 2017526698 A5 JP2017526698 A5 JP 2017526698A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- administered
- pharmaceutically acceptable
- composition
- solvate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462046502P | 2014-09-05 | 2014-09-05 | |
| US62/046,502 | 2014-09-05 | ||
| US201462082236P | 2014-11-20 | 2014-11-20 | |
| US62/082,236 | 2014-11-20 | ||
| PCT/US2015/048520 WO2016037044A1 (en) | 2014-09-05 | 2015-09-04 | Compositions and methods for treating proliferation disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019149011A Division JP6837525B2 (ja) | 2014-09-05 | 2019-08-15 | 増殖性障害を処置するための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017526698A JP2017526698A (ja) | 2017-09-14 |
| JP2017526698A5 true JP2017526698A5 (https=) | 2018-10-04 |
| JP6574245B2 JP6574245B2 (ja) | 2019-09-11 |
Family
ID=55436479
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017512759A Expired - Fee Related JP6574245B2 (ja) | 2014-09-05 | 2015-09-04 | 増殖性障害を処置するための組成物および方法 |
| JP2019149011A Expired - Fee Related JP6837525B2 (ja) | 2014-09-05 | 2019-08-15 | 増殖性障害を処置するための組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019149011A Expired - Fee Related JP6837525B2 (ja) | 2014-09-05 | 2019-08-15 | 増殖性障害を処置するための組成物および方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9949981B2 (https=) |
| EP (1) | EP3189036B1 (https=) |
| JP (2) | JP6574245B2 (https=) |
| KR (1) | KR20170045748A (https=) |
| CN (2) | CN111494378A (https=) |
| AU (2) | AU2015311751B2 (https=) |
| BR (1) | BR112017004459A2 (https=) |
| CA (1) | CA2958770A1 (https=) |
| ES (1) | ES2955926T3 (https=) |
| IL (2) | IL250715B (https=) |
| MX (1) | MX382891B (https=) |
| RU (2) | RU2019142694A (https=) |
| SG (1) | SG11201701704XA (https=) |
| WO (1) | WO2016037044A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2887243C (en) | 2012-10-15 | 2024-04-09 | Epizyme, Inc. | Methods of treating cancer |
| KR20180042356A (ko) | 2015-08-24 | 2018-04-25 | 에피자임, 인코포레이티드 | 암 치료 방법 |
| CN116068187A (zh) | 2016-03-14 | 2023-05-05 | 皮尔斯生物科技有限公司 | AKT-mTOR通路蛋白的检测和量化 |
| US11352328B2 (en) | 2016-07-12 | 2022-06-07 | Arisan Therapeutics Inc. | Heterocyclic compounds for the treatment of arenavirus |
| JP7324144B2 (ja) * | 2017-02-02 | 2023-08-09 | エピザイム，インコーポレイティド | 癌処置様式 |
| WO2019071171A1 (en) * | 2017-10-05 | 2019-04-11 | The Board Of Trustees Of The University Of Illinois | Method of treating sickle cell disease |
| CN110669015A (zh) * | 2018-07-03 | 2020-01-10 | 上海喀露蓝科技有限公司 | 一种fgfr抑制剂的制备方法 |
| AU2019379179A1 (en) * | 2018-11-16 | 2021-06-10 | Arqule, Inc. | Pharmaceutical combination for treatment of cancer |
| US12419865B2 (en) | 2018-12-06 | 2025-09-23 | Arisan Therapeutics Inc. | Compounds for the treatment of arenavirus infection |
| AU2020214258B2 (en) * | 2019-01-29 | 2025-08-28 | Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. | AKT inhibitor |
| US20220184147A1 (en) * | 2019-03-04 | 2022-06-16 | Northwestem University | Bacterial enzymatic conversion of anthracycline chemotherapeutics to reduce toxicity and promote diversity among the intestinal microbiota |
| WO2022053708A1 (en) * | 2020-09-14 | 2022-03-17 | Basilea Pharmaceutica International AG | Pharmaceutical combinations for use in the treatment of gastric adenocarcinoma |
| IL301567A (en) * | 2020-09-30 | 2023-05-01 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | A compound as an AKT KINASE inhibitor |
| CN112225745B (zh) * | 2020-11-16 | 2021-10-12 | 烟台大学 | 一种具有抗肿瘤活性的异片螺素类化合物、制备方法及用途 |
| EP4486390A1 (en) * | 2022-03-02 | 2025-01-08 | Terremoto Biosciences, Inc | Covalent modifiers of akt1 and uses thereof |
| IL326325A (en) * | 2023-08-04 | 2026-04-01 | Terremoto Biosciences Inc | 3H-Imidazo[5,4-B]pyridine compounds as non-covalent AKT1 modifiers and uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8273754B2 (en) * | 2008-12-30 | 2012-09-25 | Arqule, Inc. | Substituted 1H-pyrazolo[3,4-D]pyrimidine-6-amine compounds |
| TWI461410B (zh) * | 2008-12-30 | 2014-11-21 | Arqule Inc | 經取代之５，６－二氫－６－苯基苯並〔f〕異喹啉－２－胺化合物類 |
| AU2010232644A1 (en) * | 2009-03-31 | 2011-10-20 | Arqule, Inc. | Substituted tetrahydropyrazolo-pyrido-azepin compounds |
| CA2785536C (en) * | 2009-12-30 | 2018-02-27 | Arqule, Inc. | Substituted imidazopyridinyl-aminopyridine compounds |
| US8609688B2 (en) | 2011-06-24 | 2013-12-17 | Arqule, Inc. | Substituted imidazopyridinyl-aminopyridine compounds |
| WO2012177852A1 (en) * | 2011-06-24 | 2012-12-27 | Arqule, Inc | Substituted imidazopyridinyl compounds |
-
2015
- 2015-09-04 SG SG11201701704XA patent/SG11201701704XA/en unknown
- 2015-09-04 RU RU2019142694A patent/RU2019142694A/ru unknown
- 2015-09-04 MX MX2017002892A patent/MX382891B/es unknown
- 2015-09-04 CN CN202010227563.XA patent/CN111494378A/zh active Pending
- 2015-09-04 BR BR112017004459A patent/BR112017004459A2/pt not_active IP Right Cessation
- 2015-09-04 JP JP2017512759A patent/JP6574245B2/ja not_active Expired - Fee Related
- 2015-09-04 WO PCT/US2015/048520 patent/WO2016037044A1/en not_active Ceased
- 2015-09-04 RU RU2017111204A patent/RU2711500C2/ru active
- 2015-09-04 CN CN201580060093.XA patent/CN107074769B/zh not_active Expired - Fee Related
- 2015-09-04 US US14/845,795 patent/US9949981B2/en active Active
- 2015-09-04 AU AU2015311751A patent/AU2015311751B2/en not_active Ceased
- 2015-09-04 CA CA2958770A patent/CA2958770A1/en not_active Abandoned
- 2015-09-04 ES ES15838638T patent/ES2955926T3/es active Active
- 2015-09-04 KR KR1020177008846A patent/KR20170045748A/ko not_active Abandoned
- 2015-09-04 EP EP15838638.3A patent/EP3189036B1/en active Active
-
2017
- 2017-02-22 IL IL250715A patent/IL250715B/en active IP Right Grant
-
2019
- 2019-08-15 JP JP2019149011A patent/JP6837525B2/ja not_active Expired - Fee Related
-
2020
- 2020-06-04 AU AU2020203706A patent/AU2020203706B2/en not_active Expired - Fee Related
- 2020-08-31 IL IL277028A patent/IL277028A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017526698A5 (https=) | ||
| RU2017111204A (ru) | Композиции и способы, которые можно использовать для лечения пролиферативных заболеваний | |
| JP2019501204A5 (https=) | ||
| US20230235083A1 (en) | Combination therapy using a liv1-adc and a chemotherapeutic | |
| JP2022533578A5 (https=) | ||
| JP6002835B2 (ja) | 低用量イリノテカン塩酸塩水和物を含有する抗腫瘍剤 | |
| RU2018105655A (ru) | Комбинированная терапия с применением липосомального иринотекана и ингибитора parp для лечения рака | |
| CN108135900A (zh) | 包含瓦尼替尼及抗癌剂之组合疗法 | |
| ES2946472T3 (es) | Agente antitumoral y potenciador del efecto antitumoral | |
| ES3019570T3 (en) | Improved therapeutic index of anti-immune checkpoint inhibitors using combination therapy comprising a phy906 extract or a scutellaria baicalensis georgi (s) extract | |
| JP2015517523A5 (https=) | ||
| JP2022500479A5 (https=) | ||
| Inohara et al. | Phase 2 study of docetaxel, cisplatin, and concurrent radiation for technically resectable stage III-IV squamous cell carcinoma of the head and neck | |
| Konopka-Filippow et al. | Pain management during radiotherapy and radiochemotherapy in oropharyngeal cancer patients: single-institution experience | |
| RU2014150860A (ru) | Режим дозирования pi-3 киназы | |
| JP2024512775A5 (https=) | ||
| US20160128988A1 (en) | Combinations for the treatment of cancer comprising a mps-1 kinase inhibitor and a mitotic inhibitor | |
| JP2021511344A5 (https=) | ||
| US20060135527A1 (en) | Use of imatinib (glivec,sti-571) to inhibit breast cancer resistance protein (bcrp)-mediated resistance to therapeutic agents | |
| JP2022515249A (ja) | 癌の治療におけるドセタキセルの長期使用 | |
| JP2022514960A (ja) | ドセタキセルおよびｃｙｐ３ａ阻害剤を用いる固形腫瘍の組み合わせ治療 | |
| RU2018119085A (ru) | Схема введения ингибитора фосфатидилинозитол-3-киназы | |
| TW200603804A (en) | Treatment with irinotecan (cpt-11) and an EGFR-inhibitor | |
| Bahleda et al. | Phase I trial of bortezomib daily dose: safety, pharmacokinetic profile, biological effects and early clinical evaluation in patients with advanced solid tumors | |
| JP2006528696A (ja) | 抗癌剤の抗腫瘍活性を増強する方法 |